You searched for Antibody candidate - Page 9 of 69

Best in Biotech 24 Oct 2024

Six biotech companies advancing multiple sclerosis therapies

…debilitating disease. Table of contents Biogen Leading multiple sclerosis drug candidate of Biogen: BIIB091 Biogen is known for its pioneering work in the neuroscience field. It has been discovering and…

October 24, 2024 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 27 May 2025

Interleukin therapeutics: 9 companies to follow in 2025

…for ANK-101 at the AACR Annual Meeting Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of cytokine-based treatments. The company’s lead candidate, ANK-101 (tolododekin…

May 27, 2025 - 12 minutesmins - By Jules Adam

In Depth 22 Dec 2022

10 biotech companies to watch in 2023

…candidates — called TCR-T cell therapies — are designed to tackle solid cancers. This is because they are genetically modified to express a custom version of a T-cell protein called…

December 22, 2022 - 9 minutesmins - By Jonathan Smith

News and Trends 30 Apr 2018

Record Series B Financing Supports Antibody Cancer Therapy

…of antibody-based therapies for cancer has recently been on the rise in European biotech. For example, late last year Argenx raised €195M to support the clinical development of its antibody…

April 30, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 7 Apr 2016

Two of the Biggest European Biotechs launch Antibody Program together

…most common antibody subclass to be used in approved therapies), and has a novel mode of action with a potential to tackle inflammation. It’s also the first antibody to reach…

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 4 Jun 2020

Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle

Update (04/06/2020): After upholding four of Kymab’s patents addressing the production of antibody drugs earlier this year, the US Patent Trial and Appeal Board has rejected Regeneron’s attempt to invalidate…

June 4, 2020 - 4 minutesmins - By Anita Chakraverty

News and Trends 31 May 2017

German Biotech Enters the Clinic with Next-Generation Antibody for AML

…immunotherapy candidate, TacSyn, to treat patients at a stage of existing disease of AML as well as acute lymphoblastic leukemia (ALL). This bispecific antibody contains an anti-CD3 domain, which is…

May 31, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 8 May 2017

The EU Approves New Treatment for a Rare Pediatric Cancer

…Human Use (CHMP) has now given a positive opinion on APN311, recommending the approval of the new drug. APN311 is a monoclonal antibody targeting the neuroblastoma-specific antigen GD2. The antibody…

May 8, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 11 Oct 2016

UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies

…unabridged antibody counterparts, almost comparable to small peptides. Figure 1. A diagram of a whole antibody – Humabodies whittle these down to just the VH domain reflecting the antibody binding…

October 11, 2016 - 3 minutesmins - By Evelyn Warner

Interview 12 Feb 2018

MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert

…those compounds,” he continued. MorphoSys’ first attempt at taking its own antibody to market will be with its blood cancer candidate, MOR208, a monoclonal antibody that targets CD19, which is…

February 12, 2018 - 8 minutesmins - By Alex Dale

novimmune shire hemophilia antibody roche

News and Trends 18 Jul 2017

Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche

Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that…

July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Jul 2023

Epsilogen completes first clinical trial of IgE antibody to treat cancer

…results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target for ovarian cancer. It was…

July 27, 2023 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

Six biotech companies advancing multiple sclerosis therapies

Interleukin therapeutics: 9 companies to follow in 2025

10 biotech companies to watch in 2023

Record Series B Financing Supports Antibody Cancer Therapy

Two of the Biggest European Biotechs launch Antibody Program together

Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle

German Biotech Enters the Clinic with Next-Generation Antibody for AML

The EU Approves New Treatment for a Rare Pediatric Cancer

UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies

MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert

Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche

Epsilogen completes first clinical trial of IgE antibody to treat cancer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!